Loading
Life sciences · Journal article
Molecular Cancer · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract CD58, the primary ligand of the co-stimulatory receptor CD2, plays a crucial role in the formation of the immunological synapse (IS) and the initiation of antitumor immunity involving T cells and natural killer (NK) cells. Aberrant CD58 expression, resulting from genomic inactivation, epigenetic silencing, transcriptional repression, and post-translational modifications, disrupts the architecture of the IS, impairs T and NK cell activation and effector functions, and promotes an immunosuppressive microenvironment. Consequently, restoring CD58 expression or function has emerged as a promising therapeutic strategy, with approaches such as epigenetic drugs to reverse CD58 silencing, engineered T cells to restore CD2 co-stimulation, and neutralizing agents targeting soluble CD58. In this review, we summarize the current understanding of how CD58 expression is regulated across multiple dimensions and how its dysfunction drives immune evasion and therapy resistance. We also explore the therapeutic potential of targeting the CD58-CD2 axis in cancer treatment, aiming to provide novel theoretical insights and innovative strategies to advance cancer immunotherapy.